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Abstract  
Purpose: Breast cancer (BC) affects both genders, but is understudied in men. 
Although still rare, male BC is being diagnosed more frequently. Treatments are 
wholly informed by clinical studies conducted in women, based on assumptions that 
underlying biology is similar. 
Experimental design: A transcriptomic investigation of male and female BC was 
performed, confirming transcriptomic data in silico. Biomarkers were 
immunohistochemically assessed in 697 MBCs (n=477, training; n=220, validation 
set) and quantified in pre- and post-treatment samples from a male BC patient 
receiving Everolimus and PI3K/mTOR inhibitor.  
Results: Gender-specific gene expression patterns were identified. eIF transcripts 
were up-regulated in MBC. eIF4E and eIF5 were negatively prognostic for overall 
survival alone (Log rank; p=0.013; HR=1.77, 1.12-2.8 and p=0.035; HR=1.68, 1.03-
2.74, respectively), or when co-expressed (p=0.01; HR=2.66, 1.26-5.63), confirmed 
in the validation set. This remained upon multivariate Cox regression analysis (eIF4E 
p=0.016; HR 2.38 (1.18-4.8), eIF5 p=0.022; HR 2.55 (1.14-5.7); co-expression 
p=0.001; HR=7.04 (2.22-22.26)). Marked reduction in eIF4E and eIF5 expression 
was seen post BEZ235/Everolimus, with extended survival.  
Conclusions: Translational initiation pathway inhibition could be of clinical utility in 
male BC patients overexpressing eIF4E and eIF5. With mTOR inhibitors which target 
this pathway now in the clinic, these biomarkers may represent new targets for 
therapeutic intervention, although further independent validation is required. 
 
Keywords: breast cancer; genomics; eIF; survival; mTOR inhibitor 
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Statement of significance 
Genomic and transcriptomic analysis of four independent male breast cancer 
datasets identified upregulation of translational initiation pathway genes. eIF4E and 
eIF5 were independent predictors of survival, either alone or when co-expressed. 
Samples from a patient receiving a combination of agents targeting this pathway, 
suggests this pathway may be tractable. 
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Introduction 
The need for more refined therapeutic treatments for male breast cancer (MBC) is 
evidenced by a steady stream of publications highlighting gender specific differences 
using immunohistochemistry [1-5], genetics [6-11] and more recently, epigenetics 
[12-15]. Of note, whilst MBC is similar histologically to female breast cancer (FBC), 
with the same panel of biomarkers used to guide treatment and prognosis, more 
rigorous interrogation of the underlying genetics shows heterogeneity in MBC  as 
recognised in FBC where molecular profiling has identified different subgroups which 
correlate with varying clinical outcomes. Gene expression analysis of MBC is more 
limited. Nevertheless, genetic disparity has been reported, notably genes involved in 
extracellular matrix remodelling, metabolism and protein synthesis via genes 
involved in translational initiation, including eIF4E [10] which are often upregulated in 
MBC compared to FBC.  Further work has identified 2 distinct subgroups of MBC, 
termed luminal M1 and luminal M2, which differed from molecular subtypes seen in 
FBC [9]. This work also reported that N-acetyltransferase-1, a gene thought to be 
involved in drug metabolism, was a prognostic marker for MBC [9]. Subsequent to 
this Johansson et al documented differential driver genes in MBC vs FBC [16]. Most 
recently a distinct repertoire of genetic alterations were reported in MBC cautioning 
the application of FBC data to therapeutic application in MBC [11].  Genomic and 
immunohistochemical examination of a single MBC patient with recurrent disease 
showed a change in hormone receptor expression in the post-progression sample, 
with little change at the genomic level, whilst receiving a combination of 
BEZ235/Everolimus [17].  
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Taking advantage of our large collection of MBC samples we aimed to generate 
gene expression profiles of matched MBC and FBC samples and assess 
immunohistochemically if differences in specific biomarkers affected clinical outcome 
in men using a training set of 477 and a validation set of 220 cases. Finally we 
analysed expression of these biomarkers in pre- and post-treatment samples from a 
MBC patient who received a combination of the PI3K/mTOR inhibitors BEZ235 and 
Everolimus [17].  
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Methods 
Ethical approval and patient material 
Leeds (East) Research Ethics Committee (06/Q1205/156; 15/YH/0025) granted 
ethical approval. For gender comparison transcriptomics, cases were matched for 
age, size, nodal and survival status. Formalin-fixed paraffin-embedded male (n= 15) 
and female (n=10) primary invasive ductal carcinoma (ER-positive, HER2-negative, 
node-negative) were identified from histopathology archives. An additional 3 male 
and 3 female frozen cases were used to confirm gene expression. A training set of 
477 MBCs represented on tissue microarrays (TMAs; n= 446, constructed as 
described [1]) and 31 full faced sections, plus a validation set (220 cases on TMAs 
[9]), was used in immunohistochemistry. Patient characteristics are shown in Table 
1. Details on the datasets used in the explorative and validation phases is provided 
(Figure S1). Cases were pseudo-anonymised and data analysed anonymously. 
 
Gene expression  
Five x 10µm sections applied to Almac Diagnostics (Craigavon, UK) Breast Cancer 
DSA™ platform representing 21,808 genes, according to in house protocols [18]. 
Three MBC samples failed QC and were excluded from further analysis. Genes that 
were significantly differentially expressed between genders were calculated from 
Almac normalised and transformed data with FDR threshold of 5% and a fold-
change significance of 1%. Representative heat maps were generated from resulting 
expression data using hierarchical clustering and Pathway Ingenuity Analysis to 
identify gender-specific gene expression. The microarray data are available on 
ArrayExpress (www.ebi.ac.uk/arrayexpress), accession number E-MTAB-4040. The 
Oncomine platform was used for further data mining.  
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Immunohistochemistry  
REMARK criteria were employed [19]. Immunohistochemistry was conducted as 
previously described, using well validated antibodies [20], including: eIF1 (Abcam - 
ab118979. 1:200); eIF2 (Abcam - ab32157. 1:150); eIF3 (Abcam - ab171419. 1:150); 
eIF4E (Santa Cruz - sc-9976. 1:400); eIF5 (Abcam - ab32443. 1:300). Cases were 
batch stained for each antibody with recommended controls. TMAs were digitised 
(x40, Leica-Aperio AT2 ScanScope scanner; Leica Biosystems, UK). Each TMA core 
was viewed using in-house software and assessed semi-quantitatively for each 
biomarker taking account of staining intensity and percentage of tumour cells. 
Overall scores were averaged from either duplicate or triplicate cores which 
represented a case. Staining was generally cytoplasmic; our group has shown that 
nuclear staining is seen occasionally but is not of prognostic value [20], therefore 
only cytoplasmic staining was considered. Scoring criteria were determined from 
previously reported studies [20, 21]. Cases were scored by MPH with co-scoring of 
10% (CABS, trainee histopathologist), overseen by AMS, specialised breast 
consultant histopathologist. Where disagreement was reported (score >2; n=5) 
cases were re-reviewed to reach consensus. Excellent strength of agreement was 
observed between scorers using Inter-Class Correlation Coefficients (eIF1 0.911 
(95%CI 0.769-0.944), eIF2 0.846 (95%CI 0.736-0.910), eIF4E 0.882 (95%CI 0.755-
0.913), eIF5 0.865 (95%CI 0.769-0.922). Scores were indeterminable in 49 cases 
due to core loss/exhaustion during processing, well-recognised with TMAs.  
 
Analysis of eIF4E and eIF5 on a single patient progression series treated with 
PI3K/mTOR inhibitors 
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Pre- and post-treatment biopsies were obtained from a 66 year old Caucasian male 
diagnosed in 2006 with ER+, PR+, HER2- infiltrative papillary breast cancer whose 
clinical history has been reported [17]. Following mastectomy he received adjuvant 
tamoxifen but developed a contralateral grade 3 ER+, PR+, HER2- infiltrative ductal 
carcinoma 2 years later (pre-treatment sample). Standard adjuvant chemotherapy 
commenced, with 5 weeks of radiotherapy and subsequent adjuvant letrozole. 
Thirteen months later he developed multiple nodal and bilateral lung metastases and 
was switched to a schedule of vinorelbine plus capecitabine every 3 weeks. 
Following disease stabilisation he received fulvestrant. After 8 months, node 
progression was noted and the patient was switched to BEZ235 (200mg orally, twice 
daily) plus sub-therapeutic Everolimus (2.5mg, weekly). Aside from a skin rash this 
was well tolerated and stable disease was maintained for a further 18 months after 
which a nodal metastasis developed (post-treatment sample). eIF4E and eIF5 
expression was assessed immunohistochemically in the pre- and post-treatment 
samples, as described above and reviewed by two investigators (MPH and AMS) 
and quantified (Leica Aperio positive pixel count algorithm, version 9). 
 
Statistical analysis 
Receiver operator curves were generated to obtain relevant cut-offs [22]. 
Associations with Disease-free and Overall survival (DFS; from initial diagnosis to 
the diagnosis of local or distant recurrence, OS; from initial diagnosis to death) were 
analysed (Kaplan–Meier plots, log rank test). Hazard ratios were determined by Cox 
regression. Follow up patient information was updated in June 2013 and survival 
periods calculated. Patients were censored at the last day they were known to be 
alive. Variables were entered in univariate and multivariate analysis (Cox 
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proportional hazards regression model). Gene expression p-values were adjusted for 
multiple testing using the false discovery rate method (Benjamini-Hochberg 
procedure). 
 
Results 
Gender comparison of gene expression 
Hierarchical agglomerative clustering revealed differential gene expression patterns 
in MBC and FBC (Figure 1A). Unsupervised clustering revealed three distinct 
gender-specific clusters. The top gene cluster displayed higher expression in MBC. 
The middle cluster showed lower expression in MBC while the bottom cluster was 
over represented in MBC. Further analysis of the top cluster, showed components of 
the translational initiation machinery were overexpressed in MBC compared with 
FBC, notably genes associated with translational initiation pathway. This was 
confirmed through mining an independent MBC dataset [10] (Figure 1B) and also by 
interrogation of Oncomine™ which showed higher expression of eIF4E and eIF5 in 
breast and lung cancer compared to matched normal tissue. When these biomarkers 
were compared for gender, eIF4E and eIF5 expression was proportionately higher in 
male breast but not lung cancer (Figure S2).  
 
eIF4E and eIF5 expression are independently prognostic in MBC 
Having identified gender-specific differences in eIF gene expression, we examined 
this immunohistochemically in 697 MBCs; training set (n=477), validation set (n=220) 
[9]. Cytoplasmic expression was present in invasive tumour cells for all family 
12 
 
members examined except eIF3, which was consistently negative, despite positive 
staining of colon positive control tissue (Figure S3). Training and validation sets were 
scored semi-quantitatively for each biomarker, taking account of intensity of staining 
and percentage of positive tumour cells. Representative staining for each eIF is 
shown in Figure S3. R.O.C curves were plotted and used to determine the optimum 
cut-off value for each antibody. These were: eIF1, 5.5; eIF2, 4.75; eIF4E, 5.77; and 
eIF5, 6.41 (Figure S3).  
 
Kaplan Meier survival curves showing the impact of eIF expression on OS and DFS 
are shown (Figure 2). Expression of eIF4E and eIF5 was associated with worse OS. 
This relationship was also observed in the validation set and remained upon 
multivariate analysis in the larger training set when adjusted for age, tumour size, 
lymph node positivity and grade (Table 2), even with disparity in significance of 
lymph node status between the 2 data sets; we attribute this to differences in the 
weighting of live/dead in each dataset. Alternatively, this may reflect the lack of 
complete data on lymph node status in both cohorts (Table 1); despite our best 
efforts we were unable to obtain this. Significance remained when the training and 
validation sets were combined (n= 697 cases; Table 2). 
 
As only eIF4E and eIF5 impacted on survival we examined the effects of their co-
expression. Low expression was determined for cases with scores below the defined 
cut point; <5.77 for eIF4E and <6.41 for eIF5 (n=96). High expression; >5.77 for 
eIF4E and >6.41 for eIF5 (n=14). Cases that over-expressed eIF4E and eIF5 (>5.77, 
>6.41 respectively) had significantly shorter survival compared to those who 
expressed eIF4E and eIF5 at lower levels (<5.77, <6.41 respectively; Figure 3). 
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Cases which were high for one of the proteins fell between both curves (data not 
shown). Co-expression of eIF4E and eIF5 remained significant upon multivariate 
analysis (p=0.001, HR 7.037 (2.223 – 22.2) in the training set (Table 2). Correlations 
between eIF4E expression with PR (P<0.001) and low tumour grade (P<0.036) were 
observed, while AR correlated with eIF5 (P<0.035), with a trend towards correlation 
with PR and low grade (Table S1). No significant correlation with clinico-pathological 
parameters was observed in cases which co-expressed eIF4E and eIF5, although 
trends with lower grade and PR were suggested. 
 
BEZ235/Everolimus combination therapy alters eIF4E and 5 expression 
As overexpression of eIF4E and eIF5 was associated with reduced OS, we 
examined the effects of treatments known to impact on their signalling in a single 
MBC patient. In the pre-treatment sample, strong cytoplasmic expression of eIF4E 
and eIF5 was observed (Figure 4A, C, respectively). Strikingly in the post-treatment 
sample, a marked reduction in staining was observed for both biomarkers; 89% to 
58% (eIF4E), 87% to 35% (eIF5), accompanied by a shift in location of eIF5 from the 
cytoplasm to the nucleus (Figure 4B, D).   
 
Discussion 
To our knowledge this is the largest study in MBC reported to date, examining over 
700 cases at the transcriptomic and immunohistochemical levels across four 
independent datasets. Key findings were upregulation of genes of the translational 
initiation pathway in MBC in two independent transcriptomic screens, followed by 
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identification of eIF4E and eIF5 as independent predictors of survival, either when 
evaluated alone or when co-expressed, where there was an even stronger negative 
survival influence. We also provide evidence that the translational initiation pathway 
may be tractable by studying samples from a MBC patient who received an 
investigational combination of agents which target this pathway, namely BEZ235 and 
Everolimus. 
 
The role of initiation factors in the progression to a malignant phenotype is reported 
in many cancers including, breast, head and neck, liver, prostate, bladder, gastric, 
colon, ovarian, glioma, lymphoma, non-small cell lung carcinoma (NSCLC), cervical, 
small intestine and melanoma [20, 23-25]. This has highlighted eIFs, notably eIF4E 
as indicative of poor prognosis. Originally shown to be overexpressed in breast 
cancer [26], eIF4E is essential for translation and is a rate-limiting step in RNA 
recruitment to ribosomes [27]. Indeed, most of the direct inhibitors of the eIF 
machinery are targeted toward eIF4E [28]. Moreover, eIF4E and its associated 
binding proteins have been shown to correlate with survival duration in FBC, where 
cases with high expression of eIF4E relative to its binding proteins had significantly 
worse survival [20]. Our results corroborate these and other findings where elevated 
eIF4E expression predicts poor survival in FBC [29-31].  
Recently, 337 cases from our 477-case training set were examined independently, 
suggesting eIF4E expression had no prognostic effect in MBC [32]. This anomaly 
might be explained by the different times used to estimate survival in the 2 studies. 
In this study survival status was updated in June 2013 (by SSR) while survival data 
in the cases used by Millican-Slater et al [32] was earlier, 2008-2009, and only 
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available for 187 cases. As well as using the most up to date survival information 
available, this emphasises the need for inclusion of sufficiently large numbers of 
samples for robust validation studies when estimating the effects of biomarkers on 
survival, as widely discussed [33, 34]. The large number of cases in our training 
(n=477) and validation (n=220) cohorts with follow up on >70% as well as 
concordance with previous literature [20, 29-31] are significant strengths, all pointing 
towards eIF4E being a poor prognostic factor in breast cancer, irrespective of 
gender.  Given that we wished to identify potential gender-specific differences in 
gene expression in breast cancer, this result may be perceived as surprising. 
However there are multiple examples of biomarkers being expressed in different, or 
even the same type, of breast cancer, but which are only of clinical use when 
expressed above a certain threshold (reviewed in [35]). Interestingly, searching of 
Oncomine™ showed that eIF4E and eIF5 were not only increased in tumour versus 
normal breast and lung cancers, but that eIF4E and eIF5 expression was 
proportionately higher in MBC when genders were compared, substantiating our 
findings. However, while we have shown eIF4E and eIF5 are elevated in MBC, this 
does not preclude their expression and targeting in FBC. As we move towards 
personalised medicine, case-specific biomarker expression and their quantitative 
expression levels should help optimise tailored therapies for breast cancer in both 
genders. 
 
As reported elsewhere [36-38, 1], our MBC cohort was almost universally ER+, 
expressed in >90% of cases. As previous gene expression profiling studies indicate 
that MBC shares more features with ER- FBC than ER+ FBC [9], it is of interest to 
note that eIF4E overexpression has also been reported to negatively impact survival 
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in triple-negative FBC [39]. Thus, as well as sharing genomic similarities, this could 
indicate that ER+ MBCs share a prognostic biomarker with ER- FBC. 
 
eIF5 is essential in the translation initiation process, responsible for the association 
of eIF2 with Met-tRNA [40] yet its precise role in cancer pathogenesis remains 
elusive. To our knowledge this is the first time it has been shown to negatively affect 
survival duration in MBC. Interestingly, chromosome 3q26, the gene locus of eIF5, is 
amplified in breast cancer cell lines [41]. Both eIF4E, eIF5 and combinations 
remained significant remaining upon multivariate Cox regression analysis, however 
this significance was reduced in our validation set, which we attribute to sample size, 
as follow-up length and treatment regimens were similar in both datasets (Table 1). 
 
Despite detecting eIF3 mRNA in both MBC and FBC by qRT-PCR (data not shown), 
we were unable to detect protein expression by immunohistochemistry. Expression 
in our positive control tissue eliminated the possibility of poor antibody efficacy or 
influence of other pre-analytical factors. Nevertheless, there is immunohistochemical 
evidence that eIF3 expression is decreased in pancreatic cancer [42, 24]. Further 
evidence from cancer profiling arrays shows general downregulation of eIF3 in 
human tumours [24], which may explain its lack of expression.   
 
The recognised contribution of eIFs to tumorigenesis has led to their investigation as 
therapeutically tractable targets, particularly using antisense approaches or small 
molecule inhibitors [43]. A phase one clinical trial showed reduction of eIF4E protein 
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by up to 65% by an antisense oligonucleotide (LY2275796) in most of the 30 patients 
tested [44]. Other targets of eIFs include PI3K and mTOR inhibitors. Rapamycin and 
analogues, upstream signalling inhibitors of translation initiation, are now in the clinic 
[45-47]. We assessed eIF4E and eIF5 expression in a MBC patient who was treated 
with agents known to impact these signalling pathways, namely the mTOR inhibitor 
Everolimus (Afinitor/RAD001) given in combination with BEZ235, an inhibitor of class 
I PI3K molecules and the mTORC1 and mTORC2 complexes. This clearly 
demonstrated a striking reduction in expression of eIF4E and eIF5 (>50%) in the 
post-treatment samples. As the mTORC1/2 pathways are upstream of eIF4E [48], 
we predict their inhibition may result in declining levels of eIF proteins. Another study 
showed a reduction in eIF4E expression in approximately one third of breast cancers 
following treatment with Everolimus [49]. As over-expression of both eIF4E and eIF5 
was associated with worse overall survival in MBC, it is tempting to speculate that 
action of the BEZ235/Everolimus combination could deregulate their molecular 
pathways, resulting in reduction in their expression, leading to survival benefit, as 
stable disease was maintained for 18 months after the BEZ235/Everolimus switch. 
However it is worth noting the patient had already been heavily treated with other 
chemo and endocrine agents prior to this switch, which may have contributed to the 
reduction in eIF4E and eIF5 expression we report. Nevertheless, this intriguing result 
is supported by in vivo animal data in which suppressing mTOR activity and its 
downstream translational regulators delayed breast cancer progression [50]. Clearly 
further validation is required. Lack of specific male breast cancer cell line models, 
precludes this in vitro; potentially this could be considered in the context of MBC-
specific clinical trials e.g. as recommended by the International Male Breast Cancer 
Program [51]. Another interesting observation was the relocation of eIF5 from a 
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cytoplasmic to a nuclear location in the post-treatment sample. As the association of 
eIF2 with Met-tRNA by eIF5 occurs in the cytoplasm [40], the biological reasons for 
its presence in the nucleus is unknown. 
 
In summary, gene expression analysis revealed that, compared to FBC, genes 
involved in the translational initiation pathway are over-expressed in MBC, 
corroborated by in silico validation in an independent data set and 
immunohistochemical analysis demonstrating that over-expression of eIF4E and 
eIF5 are predictive of reduced patient survival in 697 MBCs with long term follow up. 
Together with our data on pre- and post-treatment evaluation of these biomarkers in 
a MBC patient, our findings suggest that MBCs that overexpress eIF4E and eIF5 
might be considered as candidates for treatment with agents which target the 
translation machinery in cancer. Indeed pre-clinical data support the use of inhibition 
of translation initiation as an emerging new paradigm in cancer therapy [52].   
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Table 1 
Clinicopathological data for the MBC training and validation sets  
Characteristics  Training set  
Validation set 
 
Mean age (range) 66 (30-97) 70 (23-98) 
Mean follow up, years 
(range) 3.9 (0.08-24.5) 4.6 (0.04-15) 
Treatment Various combinations of adjuvant hormonal, chemo and radiotherapy  
 
Histology 
 
Number (%) 
 
Number (%) 
Invasive 419 (88) 130 (59) 
DCIS 7 (1) 4 (2) 
Mixed 15 (3) 47 (21) 
Unknown 36 (8) 39 (18) 
Grade    
1 50 (10) 15 (7) 
2 193 (41) 98 (44) 
3 147 (31) 85 (39) 
Unknown 87 (18) 22 (10) 
Lymph node    
+ 134 (28) 78 (35) 
- 147 (31) 83 (38) 
Unknown 196 (41) 59 (27) 
ERα    
+ 404 (85) 193 (88) 
- 30 (6) 9 (4) 
Unknown 43 (9) 18 (8) 
PR    
+ 352 (74) 160 (73) 
- 74 (15) 41 (19) 
Unknown 51 (11) 19 (9) 
HER2    
+ 6 (1)* 18 (8)* 
- 291 (65 157 (71) 
Unknown 149 (34) 45 (20) 
 
*Confirmed by FISH/CISH 
 
 
 
Table 2 
Univariate and multivariate analysis of eIF4E and eIF5 expression in MBC 
Univariate analysis (all biomarkers) 
 
Variable 
Training set Validation set Combined dataset 
Hazard ratio (CI)  P-value  Hazard ratio (CI)  P-value Hazard ratio (CI)  P-value 
Grade 1.590 (1.007-2.511) 0.047 1.116 (0.849-1.466) 0.432 1.252 (1.006-1.557) 0.044 
Age 1.055 (1.032-1.079) 0.000002 1.004 (1.002-1.005)  0.000017 1.005 (1.003-1.006) 2.1E-10 
Size (>20 mm) 1.006 (0.997-1.014)  0.209 1.428 (0.990-2.059) 0.057 1.146 (1.080-2.016) 0.014 
Node positivity 1.549 (0.948-2.532)  0.081 1.150 (1.094-1.209) 4.4E-09 1.695 (1.252-2.295) 0.001 
eIF4E 1.777 (1.128-2.800) 0.013 1.564 (1.028-2.378) 0.037 2.196 (1.634-2.952) 1.4E-07 
eIF5 1.685 (1.036-2.742) 0.035 1.674 (1.003-2.793) 0.049 1.347 (0.944-1.922) 0.101 
Co-expression 2.664 (1.260-5.633) 0.01 2.228 (1.093-4.542)  0.027 2.776 (1.683-4.579) 0.00006 
 
Multivariate  analysis (EIF4E) 
 
 Training set Validation set Combined dataset  
Variable 
 
 
Hazard ratio (CI)  
 
P-value  Hazard ratio (CI)  P-value Hazard ratio (CI)  P-value 
Grade 1.002 (0.583 1.721) 
 
0.995 1.106 (0.826-1.483) 0.498 1.169 (0.902-1.515) 0.237 
Age 1.052 (1.017-1.088) 
 
0.003 1.003 (1.002-1.005)  0.0001 1.004 (1.002-1.006) 0.000005 
Size (>20 mm) 1.008 (0.997-1.019) 
 
0.173 1.223 (0.828-1.805) 0.312 1.203 (0.885-1.692) 0.290 
Node positivity 1.445 (0.739-2.822) 
 
0.282 1.131 (1.072-1.193)  0.000006 1.621 (1.150-2.286) 0.006 
eIF4E 2.380 (1.179-4.805) 
 
0.016 1.333 (0.866-2.052) 0.192 2.297 (1.576-30262) 0.00001 
 
Multivariate  analysis (EIF5) 
 
 
Variable 
 
Training set 
 
Validation set Combined dataset 
Hazard ratio (CI)  
 
P-value  Hazard ratio (CI)  P-value Hazard ratio (CI)  P-value 
Grade 
 
1.075 (0.606-1.907) 0.805 
1.065 (0.787-1.441) 0.683 
1.101 (0.843-1.437) 0.482 
Age 
 
1.070 (1.033-1.107) 0.0001 
1.003 (1.001-1.005) 0.002 
1.004 (1.002-1.005) 0.0001 
Size (>20 mm) 
 
1.008 (0.997-1.019) 0.138 
1.248 (0.833-1.870) 0.282 
1.294 (0.922-1.117) 0.136 
Node positivity 
 
1.813 (0.911-3.610) 0.09 1.134 (1.073-1.198) 
 
0.000008 
 
1.621 (1.150- 2.286) 0.007 
eIF5 
 
2.552 (1.142-5.702) 0.022 1.528 (0.881-2.650) 
 
0.131 
 
2.267 (1.576-3.262) 0.044 
 
Multivariate  analysis (co-expression of EIF4E and EIF5) 
 
 
Variable 
Training set 
 
Validation set Combined dataset 
Hazard ratio (CI)  
 
P-value  Hazard ratio (CI)  P-value Hazard ratio (CI)  P-value 
Grade 
 
0.391 (0.137-1.114) 0.079 1.692 (0.858-3.336) 
 
0.129 
 
0.865 (0.508-1.472) 0.592 
Age 1.039 (0.992-1.088) 0.104 1.003 (1.001-1.006) 0.01 1.004 (1.002-1.007) 0.001 
   
Size (>20 mm) 
 
1.008 (0.991-1.026) 0.34 2.530 (1.170-5.472) 
 
0.018 
 
1.869 (1.040-30360) 0.037 
Node positivity 
 
2.927 (0.953-8.992) 0.061 1.620 (1.235-2.125) 
 
0.0004 
 
2.580 (1.348-4.937) 0.004 
Co-expression 
 
7.037 (2.223-22.269) 0.001 1.650 (0.724-3.757) 
 
0.233 
 
30343 (1.791-6.242) 0.0001 
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Figure legends 
Figure 1 
Identification of eIF pathway up regulation in MBC by hierarchical clustering and 
validation in an external dataset  
(A) Heatmap showing gender specific hierarchical clustering of differentially expressed 
genes in female (pink) and male (blue) breast cancers with exploded view of eIF genes 
which were significantly over-expressed in MBC on the right (P < 0.0001; eIF pathway genes 
and P = 0.016; FDR).  (B) Hierarchical clustering of a reanalysis of the Callari et al dataset 
[10] similarly identified members of the eIF family were overexpressed in MBC as shown in 
the exploded view on the right. Green = over-expression; red = under-expression. 
 
Figure 2 
The effect of eIF expression on disease-free and overall survival in MBC by Kaplan-
Meier survival analysis 
Effects on OS are shown in A, C, E, G and DFS in B, D, F, H.  A, B = eIF1; C, D; eIF2; E, F 
= eIF4E; G, H = eIF5. Black line = high expression, Grey line = low expression, dichotomised 
by R.O.C. analysis and analysed by log rank test. 
 
Figure 3  
Co-expression of eIF4E and eIF5 significantly impacts on MBC survival by Kaplan-
Meier survival analysis 
Cases which co-expressed eIF4E and eIF5 were stratified into low (score <5.77, <6.41 
respectively; n=96) or high (score >5.77, >6.41 respectively; n=14) expression.  Cases that 
2 
 
over-expressed eIF4E and eIF5 had significantly shorter survival compared to those who 
expressed eIF4E and eIF5 at lower levels. Black line = high expression, Grey line = lower 
expression, log rank test. 
 
Figure 4 
BEZ235/Everolimus combination therapy reduces eIF4E and eIF5 expression 
A – D i) display eIF4E and eIF5, expression in BEZ235/Everolimus pre- and post-treatment 
patient samples, respectively. A – D ii) show exploded views of a higher magnification of 
eIF4E and eIF5 staining in pre- and post-treatment patient samples respectively. A – D iii) 
display the positive pixel counting analysis images of the eIF4E and eIF5 higher 
magnification images from for pre- and post-treatment patient samples respectively. Scales 
on images A-D i) =300 µm, those on higher magnification and positive pixel analysis images 
= 60 µm. 
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